DTX3L E3 ligase: Molecular functions, regulatory mechanisms, and potential as a novel cancer biomarker and

Jiang Liangqian1, Mu Haiyu2, Xing Huixia3

  • 1Department of Laboratory Medicine, Linyi Peoples' Hospital, Linyi, Shandong, China.

Insights

Deltex E3 ubiquitin ligase 3 L (DTX3L) is crucial for cellular homeostasis and implicated in various cancers. DTX3L

Area of Science:

  • Molecular Biology
  • Cellular Biology
  • Oncology

Background:

  • The ubiquitin-proteasome pathway regulates protein stability via ubiquitination.
  • E3 ubiquitin ligases, like DTX3L, are key in substrate-specific degradation.
  • DTX3L dysregulation is linked to multiple cancer types.

Purpose of the Study:

  • To review the molecular mechanisms of DTX3L in cancer.
  • To highlight DTX3L's role in modulating oncogenic and tumor-suppressive substrates.
  • To explore DTX3L as a potential therapeutic target in oncology.

Main Methods:

  • Literature review of studies on DTX3L.
  • Synthesis of current knowledge on DTX3L's functions.
  • Analysis of DTX3L's role in various malignancies.

Main Results:

  • DTX3L modulates proliferation, cell cycle, migration, invasion, and apoptosis.
  • DTX3L influences the stability of key cancer-related proteins.
  • DTX3L is implicated in cervical cancer, melanoma, prostate cancer, and others.

Conclusions:

  • DTX3L is a promising therapeutic target and biomarker for cancer.
  • Understanding DTX3L mechanisms offers opportunities for novel drug design.
  • Further validation is needed for clinical translation of DTX3L-targeted therapies.

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.9K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K